Article Text

Download PDFPDF
Cost-effectiveness study
Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection
  1. Diego Ripamonti
  1. Infectious Diseases Unit, Azienda Ospedaliera Papa Giovanni XXIII, Piazza, Italy
  1. Correspondence to: Dr Diego Ripamonti, Infectious Diseases Unit, Azienda Ospedaliera Papa Giovanni XXIII, Piazza OMS 1, Bergamo 24127, Italy; diego.ripamonti{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrl.


Over the last 20 years, little has changed in terms of HIV treatment paradigm, being a three-drug regimen the standard of care for initial therapy. However, for reasons of virological plausibility, toxicity and costs, clinical researchers have explored the alternatives of switching virologically controlled patients to less-drug regimens (ie, dual or monotherapy). Several randomised trials1 investigated the ritonavir-boosted protease inhibitor monotherapy (PI-mono), on the grounds of absence of resistance mutations …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.